<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475513</url>
  </required_header>
  <id_info>
    <org_study_id>HM13769</org_study_id>
    <nct_id>NCT01475513</nct_id>
  </id_info>
  <brief_title>Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women</brief_title>
  <official_title>Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Birth control pills are the most commonly used method of birth control. The purpose of this
      research study is to examine whether birth control pills change heart disease risk and how
      the body handles blood sugar when given to different women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The oral contraceptive pill is the most commonly used birth control method. It is debated
      whether the birth control pill affects how the body handles insulin and sugar, or whether the
      pill changes heart disease risk. The goal of this study is to evaluate whether certain
      factors, such as how the body processes hormones, and demographic factors (e.g. body weight
      and race), influence how the pill affects the handling of insulin and sugar, and heart
      health.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 28, 2014</completion_date>
  <primary_completion_date type="Actual">May 28, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Same drug (orthocyclen) was administered to 2 groups (Caucasian women of reproductive age, and African American women of reproductive age)</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Insulin Sensitivity</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Insulin sensitivity from Frequently sampled IV glucose tolerance test (FSIVGTT), change from baseline to 6 months. Higher values indicate better insulin sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow-mediated Vasodilatation</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change Flow-mediated Vasodilatation from baseline to 6 months. Higher values indicate less cardiovascular risk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Carotid Intima Media Thickness</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Change in Carotid Intima Media Thickness from baseline to 6 months, measured on the right carotid artery, posterior. Lower values indicate better cardiovascular risk profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Acute Insulin Response to Glucose</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Acute Insulin Response to Glucose values obtained from FSIVGTT models--higher values indicate better insulin response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose Effectiveness</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Obtained from FSIVGTT models--higher values indicate better effectiveness of glucose inducing its own disposition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disposition Index at 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Modeled from FISVGTT--higher values indicate better glucose disposition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Higher fasting insulin values indicate an increased metabolic risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Glucose at 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Higher fasting glucose indicate an increased metabolic risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Areas-under-the-curve for Insulin at 6 Months</measure>
    <time_frame>Baselines, 6 months</time_frame>
    <description>Measured during oral glucose tolerance test. Higher values indicate increased metabolic risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Areas-under-the-curve for Glucose</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Measured during oral glucose tolerance test. Higher values indicate increased metabolic risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Higher value indicates increased cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL at 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Lower values indicate increased cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Mass Index in 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Higher values indicate higher metabolic risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Higher value indicates higher cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Higher value indicates higher cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Higher values indicate higher cardiovascular risk</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Cardiovascular Risk</condition>
  <condition>Perimenopausal Disorder</condition>
  <arm_group>
    <arm_group_label>African-American women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>African-American women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caucasian women</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ortho Cyclen®</intervention_name>
    <description>Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
    <arm_group_label>African-American women</arm_group_label>
    <arm_group_label>Caucasian women</arm_group_label>
    <other_name>Orthocyclen</other_name>
    <other_name>Sprintec</other_name>
    <other_name>Previfem</other_name>
    <other_name>MonoNessa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal, regular-cycling women 18-35 years

          -  Either African-American or Caucasian (African-American and Caucasian women will be
             BMI-matched)

          -  non-smoker.

        Exclusion Criteria:

          -  Diabetes

          -  Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric,
             infectious, and malignant disease

          -  Contraindications to oral contraceptive use (history of blood clots, heart attacks or
             stroke, vascular disease, coagulopathy, prolonged immobilization, breast cancer,
             migraine head-aches, major surgery within past 6 months, blood pressure &gt;160/100 mmHg,
             pregnancy or lactation)

          -  Use of hormonal contraceptives, glucose-lowering medications, anti-hyperlipidemic,
             anti-hypertensive or other vasoactive drugs within previous 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Cheang, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <results_first_submitted>June 12, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2018</results_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral contraceptive</keyword>
  <keyword>birth control pill</keyword>
  <keyword>women</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>endothelial function</keyword>
  <keyword>estrogen metabolism</keyword>
  <keyword>racial difference</keyword>
  <keyword>glucose intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>African-American Women</title>
          <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) took one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
        </group>
        <group group_id="P2">
          <title>Caucasian Women</title>
          <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) took one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>African-American Women</title>
          <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) took one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
        </group>
        <group group_id="B2">
          <title>Caucasian Women</title>
          <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) took one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="3.43"/>
                    <measurement group_id="B2" value="21.6" spread="3.92"/>
                    <measurement group_id="B3" value="21.0" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Insulin Sensitivity</title>
        <description>Insulin sensitivity from Frequently sampled IV glucose tolerance test (FSIVGTT), change from baseline to 6 months. Higher values indicate better insulin sensitivity</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) took one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) took one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Sensitivity</title>
          <description>Insulin sensitivity from Frequently sampled IV glucose tolerance test (FSIVGTT), change from baseline to 6 months. Higher values indicate better insulin sensitivity</description>
          <units>min ^ -1 / mIU / L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" lower_limit="-5.63" upper_limit="1.80"/>
                    <measurement group_id="O2" value="-5.63" lower_limit="-9.47" upper_limit="-1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow-mediated Vasodilatation</title>
        <description>Change Flow-mediated Vasodilatation from baseline to 6 months. Higher values indicate less cardiovascular risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>Data based on images. Some participants images could not be analyzed numerically.</population>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow-mediated Vasodilatation</title>
          <description>Change Flow-mediated Vasodilatation from baseline to 6 months. Higher values indicate less cardiovascular risk</description>
          <population>Data based on images. Some participants images could not be analyzed numerically.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0503" lower_limit="-0.0905" upper_limit="0.19099"/>
                    <measurement group_id="O2" value="-0.0210" lower_limit="-0.0868" upper_limit="0.04479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Carotid Intima Media Thickness</title>
        <description>Change in Carotid Intima Media Thickness from baseline to 6 months, measured on the right carotid artery, posterior. Lower values indicate better cardiovascular risk profile</description>
        <time_frame>baseline, 6 months</time_frame>
        <population>Data based on images. Some participants images could not be analyzed numerically.</population>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Carotid Intima Media Thickness</title>
          <description>Change in Carotid Intima Media Thickness from baseline to 6 months, measured on the right carotid artery, posterior. Lower values indicate better cardiovascular risk profile</description>
          <population>Data based on images. Some participants images could not be analyzed numerically.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00008" lower_limit="-0.0054" upper_limit="0.00523"/>
                    <measurement group_id="O2" value="0.00118" lower_limit="-0.0024" upper_limit="0.00472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Acute Insulin Response to Glucose</title>
        <description>Acute Insulin Response to Glucose values obtained from FSIVGTT models--higher values indicate better insulin response</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Acute Insulin Response to Glucose</title>
          <description>Acute Insulin Response to Glucose values obtained from FSIVGTT models--higher values indicate better insulin response</description>
          <units>mIU* L^-1 * min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.6" lower_limit="-251.0" upper_limit="179.77"/>
                    <measurement group_id="O2" value="0.48" lower_limit="-88.4" upper_limit="89.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose Effectiveness</title>
        <description>Obtained from FSIVGTT models--higher values indicate better effectiveness of glucose inducing its own disposition</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose Effectiveness</title>
          <description>Obtained from FSIVGTT models--higher values indicate better effectiveness of glucose inducing its own disposition</description>
          <units>1000 * min ^ -1</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0255" lower_limit="-0.0450" upper_limit="-0.0059"/>
                    <measurement group_id="O2" value="-0.0078" lower_limit="-0.0134" upper_limit="-0.0022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disposition Index at 6 Months</title>
        <description>Modeled from FISVGTT--higher values indicate better glucose disposition</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disposition Index at 6 Months</title>
          <description>Modeled from FISVGTT--higher values indicate better glucose disposition</description>
          <units>AIRG * Si</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-911.73" lower_limit="-2005" upper_limit="181.04"/>
                    <measurement group_id="O2" value="-834.53" lower_limit="-1963" upper_limit="294.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at 6 Months</title>
        <description>Higher fasting insulin values indicate an increased metabolic risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at 6 Months</title>
          <description>Higher fasting insulin values indicate an increased metabolic risk</description>
          <units>uIU/ mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" lower_limit="0.568" upper_limit="2.743"/>
                    <measurement group_id="O2" value="1.45" lower_limit="0.363" upper_limit="2.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Glucose at 6 Months</title>
        <description>Higher fasting glucose indicate an increased metabolic risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Glucose at 6 Months</title>
          <description>Higher fasting glucose indicate an increased metabolic risk</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-3.98" upper_limit="3.16"/>
                    <measurement group_id="O2" value="03" lower_limit="-3.46" upper_limit="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Areas-under-the-curve for Insulin at 6 Months</title>
        <description>Measured during oral glucose tolerance test. Higher values indicate increased metabolic risk</description>
        <time_frame>Baselines, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Areas-under-the-curve for Insulin at 6 Months</title>
          <description>Measured during oral glucose tolerance test. Higher values indicate increased metabolic risk</description>
          <units>mIU/mL * min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="760.6" lower_limit="-271.8" upper_limit="1733.1"/>
                    <measurement group_id="O2" value="1062.1" lower_limit="29.7" upper_limit="2094.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Areas-under-the-curve for Glucose</title>
        <description>Measured during oral glucose tolerance test. Higher values indicate increased metabolic risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Areas-under-the-curve for Glucose</title>
          <description>Measured during oral glucose tolerance test. Higher values indicate increased metabolic risk</description>
          <units>mg/dL * min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443.4" lower_limit="-623.7" upper_limit="1510.4"/>
                    <measurement group_id="O2" value="514.2" lower_limit="-552.8" upper_limit="1581.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at 6 Months</title>
        <description>Higher value indicates increased cardiovascular risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at 6 Months</title>
          <description>Higher value indicates increased cardiovascular risk</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="-2.11" upper_limit="7.05"/>
                    <measurement group_id="O2" value="-1.4" lower_limit="-6.00" upper_limit="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL at 6 Months</title>
        <description>Lower values indicate increased cardiovascular risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL at 6 Months</title>
          <description>Lower values indicate increased cardiovascular risk</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="3.69" upper_limit="9.94"/>
                    <measurement group_id="O2" value="6.9" lower_limit="2.96" upper_limit="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Mass Index in 6 Months</title>
        <description>Higher values indicate higher metabolic risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Mass Index in 6 Months</title>
          <description>Higher values indicate higher metabolic risk</description>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" lower_limit="-0.886" upper_limit="0.253"/>
                    <measurement group_id="O2" value="0.39" lower_limit="-0.669" upper_limit="1.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure From Baseline to 6 Months</title>
        <description>Higher value indicates higher cardiovascular risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline to 6 Months</title>
          <description>Higher value indicates higher cardiovascular risk</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-2.64" upper_limit="3.89"/>
                    <measurement group_id="O2" value="2.44" lower_limit="-0.83" upper_limit="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL From Baseline to 6 Months</title>
        <description>Higher value indicates higher cardiovascular risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL From Baseline to 6 Months</title>
          <description>Higher value indicates higher cardiovascular risk</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="5.71" upper_limit="21.04"/>
                    <measurement group_id="O2" value="17.1" lower_limit="6.10" upper_limit="28.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides From Baseline to 6 Months</title>
        <description>Higher values indicate higher cardiovascular risk</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African-American Women</title>
            <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
          <group group_id="O2">
            <title>Caucasian Women</title>
            <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides From Baseline to 6 Months</title>
          <description>Higher values indicate higher cardiovascular risk</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="-3.78" upper_limit="30.28"/>
                    <measurement group_id="O2" value="29.3" lower_limit="4.23" upper_limit="54.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post-baseline follow-up phone call at 10 days</time_frame>
      <desc>Superficial venous thrombosis at IV site</desc>
      <group_list>
        <group group_id="E1">
          <title>African-American Women</title>
          <description>African-American women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
        </group>
        <group group_id="E2">
          <title>Caucasian Women</title>
          <description>Caucasian women
Ortho Cyclen®: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) was taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects analyzed. Some subjects did not have reportable carotid intima media thickness and flow mediated dilatation values.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kai Cheang</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>8049863269</phone>
      <email>kicheang@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

